|
WO2020249757A1
|
|
Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
|
|
GB202005540D0
|
|
Antibodies specific to domain D of tenascin C
|
|
GB202004836D0
|
|
Interleukin-15 and interleukin-15 receptor alpha sushi domain conjugates
|
|
GB202004840D0
|
|
Interleukin-15 Conjugates
|
|
WO2020070150A1
|
|
Il2 immunoconjugates
|
|
WO2019185792A1
|
|
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
|
TW201934136A
|
|
EDB targeting IL-12 compositions
|
|
EP3660039A1
|
|
Il2 immunoconjugates
|
|
GB201812127D0
|
|
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
|
WO2018224550A1
|
|
Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
|
|
GB201805138D0
|
|
Cancer treatent using immunoconjugates and immune check-point inhibitors
|
|
AU2018224486A1
|
|
Immunocytokine combination therapy
|
|
AU2018226215A1
|
|
Immunoconjugates with optimized linkers and orientation
|
|
EP3502139A1
|
|
Antibodies to tumour antigens
|
|
EP3538547A1
|
|
Il2 and tnf mutant immunoconjugates
|
|
WO2018069467A1
|
|
Novel interleukin 4 immunoconjugates
|
|
GB201716594D0
|
|
Vascular endothelial growth factor fusion proteins
|
|
GB201712916D0
|
|
IL2 and TNF mutant immunoconjugates
|
|
GB201712755D0
|
|
Novel interleukin Immunoconjugates
|
|
GB201709206D0
|
|
Immunoconjugates with optimized linkers and orientation
|
